3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
2
NET
1
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
60
Neoplasms
7
Gastro-enteropancreatic neuroendocrine tumor
7
Carcinoid Tumor
6
Breast Neoplasms
6
Pheochromocytoma
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Adenoma, Islet Cell
5
Urinary Bladder Neoplasms
4
Thyroid Neoplasms
4
Paraganglioma
4
Neoplasm Metastasis
4
Lung Neoplasms
4
Carcinoma, Neuroendocrine
4
Carcinoma, Hepatocellular
4
Brain Neoplasms
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Melanoma
3
Carcinoma, Medullary
3
Adrenocortical Carcinoma
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Sarcoma
2
Neuroectodermal Tumors, Primitive
2
Lymphoma
2
Liver Neoplasms
2
Interventions
lanreotide
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Acromegaly
×
NET
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled